A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer
Sponsor: Hoffmann-La Roche
A PHASE4 clinical study on Non-Squamous Non-Small Cell Lung Cancer, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 8 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE4
-
Nov 2025 — Dec 2025 [monthly]
Completed PHASE4
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aarau, Switzerland , Aarhus, Denmark , Aberdeen, United Kingdom , Aix-en-Provence, France , Alcorcón, Spain , Alicante, Spain , Ancona, Italy , Ankara, Turkey (Türkiye) , Arezzo, Italy and 295 more locations